• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.

作者信息

Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, Asaoku H, Takihara Y, Kimura A

出版信息

Leukemia. 2012 Feb;26(2):365-7. doi: 10.1038/leu.2011.205. Epub 2011 Aug 12.

DOI:10.1038/leu.2011.205
PMID:21836610
Abstract
摘要

相似文献

1
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.使用针对CD38的嵌合受体进行T细胞免疫疗法可有效消除骨髓瘤细胞。
Leukemia. 2012 Feb;26(2):365-7. doi: 10.1038/leu.2011.205. Epub 2011 Aug 12.
2
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.嵌合受体抗 CD19 或抗 CD38 联合利妥昔单抗的 T 细胞免疫治疗对 B 细胞非霍奇金淋巴瘤的协同和持续作用。
Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.
3
Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.针对B细胞非霍奇金淋巴瘤中CD38的嵌合受体激活T细胞介导的免疫疗法。
J Immunother. 2009 Sep;32(7):737-43. doi: 10.1097/CJI.0b013e3181adaff1.
4
Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.用于多发性骨髓瘤免疫治疗的工程化抗CD38单克隆抗体。
J Immunol. 1995 Jul 15;155(2):925-37.
5
Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.从多发性骨髓瘤患者中产生针对HM1.24的强效抗肿瘤细胞毒性T淋巴细胞。
Clin Cancer Res. 2005 May 1;11(9):3377-84. doi: 10.1158/1078-0432.CCR-04-0650.
6
Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia.白血病B细胞而非非白血病T细胞上CD38的表达水平随时间推移相对稳定，并可预测慢性淋巴细胞白血病患者的疾病进程。
Leuk Res. 2009 Jun;33(6):775-8. doi: 10.1016/j.leukres.2008.09.001. Epub 2008 Oct 14.
7
CD38 as an immunotherapeutic target in multiple myeloma.CD38 作为多发性骨髓瘤的免疫治疗靶点。
Expert Opin Biol Ther. 2018 Dec;18(12):1209-1221. doi: 10.1080/14712598.2018.1544240. Epub 2018 Nov 13.
8
Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.多发性骨髓瘤中肿瘤性浆细胞的多参数流式细胞术分析。
Cytometry B Clin Cytom. 2010 Sep;78(5):338-47. doi: 10.1002/cyto.b.20523. Epub 2010 Apr 28.
9
Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.流式细胞术检测多发性骨髓瘤患者骨髓、外周血及外周血干细胞采集中的非整倍体CD38(++)浆细胞和CD19(+) B淋巴细胞。
Leuk Res. 2004 May;28(5):469-77. doi: 10.1016/j.leukres.2003.09.015.
10
Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.靶向热休克蛋白用于多发性骨髓瘤的免疫治疗：利用负载肿瘤源性gp96的树突状细胞产生骨髓瘤特异性细胞毒性T淋巴细胞
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8808-15. doi: 10.1158/1078-0432.CCR-05-1553.

引用本文的文献

1
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.过继性细胞免疫疗法的进展及多发性骨髓瘤的治疗突破。
Exp Hematol Oncol. 2024 Oct 28;13(1):105. doi: 10.1186/s40164-024-00576-6.
2
Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma.嵌合抗原受体T细胞：复发/难治性多发性骨髓瘤的现状与未来方向综述
Front Oncol. 2024 Aug 8;14:1455464. doi: 10.3389/fonc.2024.1455464. eCollection 2024.
3
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.
嵌合抗原受体 T 细胞疗法治疗 T 细胞急性淋巴细胞白血病。
Haematologica. 2024 Jun 1;109(6):1677-1688. doi: 10.3324/haematol.2023.283848.
4
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma.超越BCMA：多发性骨髓瘤中CAR-T细胞疗法的下一波浪潮。
Front Oncol. 2024 May 10;14:1398902. doi: 10.3389/fonc.2024.1398902. eCollection 2024.
5
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.BCMA/CD47 双靶向通用 CAR-T 细胞在多发性骨髓瘤中表现出优异的抗肿瘤活性。
J Nanobiotechnology. 2024 May 23;22(1):279. doi: 10.1186/s12951-024-02512-6.
6
CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.不同启动子驱动的 CD38 特异性 CAR 整合到 CD38 基因座可导致 T 和 NK 细胞产生不同的抗肿瘤活性。
Adv Sci (Weinh). 2023 Sep;10(27):e2207394. doi: 10.1002/advs.202207394. Epub 2023 Jul 23.
7
Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.肿瘤免疫微环境中NAD途径相关分子的机制研究与治疗进展
Cancer Cell Int. 2022 Jul 30;22(1):242. doi: 10.1186/s12935-022-02664-1.
8
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.一种针对复发或难治性多发性骨髓瘤的靶向 BCMA 和 CD38 的双特异性 CAR-T 细胞疗法。
J Hematol Oncol. 2021 Oct 9;14(1):161. doi: 10.1186/s13045-021-01170-7.
9
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma.靶向CD38的新型嵌合抗原受体T细胞对多发性骨髓瘤治疗作用的表征
Front Oncol. 2021 Aug 26;11:703087. doi: 10.3389/fonc.2021.703087. eCollection 2021.
10
The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era.“魔弹”来了？化疗时代余晖下的血液系统恶性肿瘤细胞免疫治疗
Cells. 2021 Jun 15;10(6):1511. doi: 10.3390/cells10061511.